BOCA RATON, Fla., Feb. 6 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced it will hold a conference call on Wednesday, February 8, 2006 at 4:30 pm EST. Thomas H. McLain, chairman, chief executive officer and president; Raafat Fahim, Ph.D., senior vice president, research, technical and production operations; and Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, will discuss the technical aspects of the company's various pipeline programs including NicVAX, Civacir and its S. epidermidis Vaccine.
As previously announced, the operational review of Nabi Biopharmaceuticals' 2005 fourth quarter and year-end financial results will take place on Thursday, February 23, 2006 at 4:30 pm EST.
The February 8th live webcast can be accessed at http://invite.mshow.com/findshow.aspx?usertype=0&cobrand=100&shownumber=289344 or via the Nabi Biopharmaceuticals website http://www.nabi.com/. If you do not have Internet access, the U.S./Canada call-in number is 877-569-0953 conference code 5227223, and the international call-in number is 706-634-4967 conference code 5227223. An audio replay will be available for U.S./Canada callers at 800-642-1687 conference code 5227223, and for international callers at 706-645-9291 conference code 5227223.
An archived version of the webcast will be available at the same Internet address through March 2, 2006. The audio replay will also be available through March 2, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are focusing on developing products addressing commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and pre-clinical development. The company also filed Marketing Authorization Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo, which is already marketed in the United States. The company's products in development include NicVAX(TM) (Nicotine Conjugate Vaccine), a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com/.
First Call Analyst:
FCMN Contact: njohnson@nabi.com
